Ascletis Completes Dosing in U.S. Obesity Study of ASC47 Combined with Semaglutide

Ascletis Completes Dosing in U.S. Obesity Study of ASC47 Combined with Semaglutide

By, Admin 15 July 2025

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

Overview

Ascletis Pharma Inc. (HKEX: 1672, ""Ascletis"") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) evaluating the safety, tolerability and preliminary efficacy at Day 29 of single-dose, ultra-long-acting subcutaneously (SQ) administered ASC47 in combination with semaglutide in participants with obesity who do not have type 2 diabetes. The total time to enroll all the 28 participants was less than two months. The study, conducted in the U.S., consists of three cohorts with single ascending doses (10 mg, 30 mg and 60 mg) of ASC47 or volume-matched placebo. Participants in each cohort also receive four doses of semaglutide (0.5 mg, once weekly).

Words from Jinzi J. Wu: CEO of Ascletis

The rapid pace of enrollment underscores the interest in developing new treatment options for obesity and the potential advantages combination therapies may offer,"" said Jinzi J. Wu, Ph.D., Founder, Chairman and CEO of Ascletis. ""We remain on track to provide topline data from the trial in the fourth quarter of 2025.""

ASC47 Outperforms Leading Therapies in Fat Reduction and Weight Loss Models

  • ASC47 is an adipose-targeted, ultra-long-acting SQ injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. 
  • ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. 
  • As demonstrated in diet-induced obese (DIO) mouse model, high drug concentrations of ASC47 in the adipose tissue reduced significantly more fat mass than semaglutide (63.5% vs 39.6%, p=0.007) and tirzepatide (68.0% vs 50.4%, p=0.01) (Press Release). 
  • ASC47 monotherapy demonstrated a half-life of up to 40 days in a Phase Ib study (NCT06427590) in participants with obesity (Press Release). 
  • In a head-to-head DIO mouse model, low dose ASC47 in combination with semaglutide demonstrated a 56.7% greater reduction in body weight with muscle preservation compared to semaglutide monotherapy (Press Release).

Topline data from this combination study of ASC47 with semaglutide are expected in the fourth quarter of 2025.

About ASC47-103 Study

  • The ASC47-103 study, conducted in the U.S., is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability and preliminary efficacy of single-dose, ultra-long-acting subcutaneously (SQ) administered ASC47 in combination with semaglutide in participants with obesity (body mass index ≥ 30 kg/m2).  
  • The ASC47-103 study consists of three cohorts: Cohort 1 participants receive a single dose of 10 mg ASC47, or volume-matched placebo via SQ injection, and four doses of semaglutide (0.5 mg, once-weekly) via SQ injection. 
  • Cohort 2 participants receive a single dose of 30 mg ASC47, or volume-matched placebo via SQ injection, and four doses of semaglutide (0.5 mg, once-weekly) via SQ injection. 
  • Cohort 3 participants receive a single dose of 60 mg ASC47, or volume-matched placebo via SQ injection, and four doses of semaglutide (0.5 mg, once-weekly) via SQ injection.

About Ascletis Pharma Inc.

  • Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. 
  • Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist in development as a once-daily oral tablet and once-monthly subcutaneous injection for weight management. 
  • Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!